Krystal Biotech

KRYS

$
244.65
(
-0.9
%)
(
+
-0.9
%)
+
-39.4
%
148.28
NASDAQ

Last Price

12/12/25, 09:30 AM
 EDT

Margin of Safety

Current Compounder
$
148.28

PORTFOLIO CATEGORY

Modeled fair value

Up to 10%
$4.499 billion

Allocation Suggestion

Modeled fair value

Model Basis

LAST REFINED:
June 18, 2025
The current model INCLUDES the following assets and assumptions:
The current model is based on operating metrics, including:
  • Component A: Full-year 2025 revenue of $385.683 million and net income of $155.538 million.
The current model EXCLUDES the following assets:
  • KB105 in lamellar ichthyosis (phase 1/2)
  • KB407 in cystic fibrosis (phase 1/2)
  • KB408 in alpha-1 antitrypsin (A1AT) deficiency (phase 1/2)
  • KB707 in solid tumors of the lung (phase 1/2)
  • KB803 in ocular complications of dystrophic epidermolysis bullosa (DEB) (phase 3, label expansion for Vjuvek)
  • KB801 in neurotrophic keratitis (phase 1/2)

Research Deep Dive

Last Updated:

Overview

Solt DB Invest will introduce Base Research for our coverage ecosystem over the next month to coincide with third-quarter 2023 earnings announcements. Check back soon!

Technology Platform

Pipeline

Portfolio

Opportunities & Advantages

Challenges & Risks

Development Risk 

Regulatory Risk 

Commercial Risk 

Dilution Risk 

Valuation Risk 

Geopolitical Risk 

Unique Risks 

Modeling Insights

News Flow & Timing